Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entheon Biomedical Corp ENTBF


Primary Symbol: C.ENBI

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.

Recent & Breaking News (CSE:ENBI)

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Newsfile January 19, 2021

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

Newsfile January 14, 2021

Entheon Biomedical Engages Star Finance GmbH for Investor Relations

Newsfile January 12, 2021

Entheon Biomedical (CSE:ENBI) hires media personality DJ Skee as advisor

Simon Druker  January 11, 2021

KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021

PR Newswire January 11, 2021

Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor

Newsfile January 11, 2021

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

Newsfile January 4, 2021

Entheon Biomedical Closes Private Placement

Newsfile December 25, 2020

Entheon Biomedical Announces Private Placement

Newsfile December 18, 2020

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs

Livemoney December 11, 2020

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

Newsfile December 9, 2020

Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

Newsfile December 4, 2020

Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

Newsfile December 1, 2020

Entheon Biomedical to Begin Trading on the Frankfurt Exchange

Newsfile November 26, 2020

Eric Sprott Announces Holdings in Entheon Biomedical Corp. (formerly, MPV Exploration Inc.)

Newsfile November 12, 2020

Targeting Addiction's Cause, Not Symptoms, Entheon Biomedical a Must See as it Comes Public

Livemoney November 12, 2020

Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange

Newsfile November 12, 2020

CSE Bulletin: Fundamental Change - MPV Explorations Inc./Entheon Biomedical Corp.

Newsfile November 11, 2020

Entheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange

Newsfile November 5, 2020

MPV announces CSE's conditional approval of its transaction with Entheon Biomedical Corp.

GlobeNewswire October 28, 2020